DE69935085D1 - Method and composition for inhibiting neoplastic cell growth - Google Patents
Method and composition for inhibiting neoplastic cell growthInfo
- Publication number
- DE69935085D1 DE69935085D1 DE69935085T DE69935085T DE69935085D1 DE 69935085 D1 DE69935085 D1 DE 69935085D1 DE 69935085 T DE69935085 T DE 69935085T DE 69935085 T DE69935085 T DE 69935085T DE 69935085 D1 DE69935085 D1 DE 69935085D1
- Authority
- DE
- Germany
- Prior art keywords
- present
- polypeptides
- methods
- cell growth
- neoplastic cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Abstract
The present invention concerns methods and compositions for inhibiting neoplastic cell growth. In particular, the present invention concerns antitumor compositions and methods for the treatment of tumors. The invention further concerns screening methods for identifying growth inhibitory, e.g., antitumor compounds. In addition, the present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Applications Claiming Priority (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11329698P | 1998-12-22 | 1998-12-22 | |
US113296P | 1998-12-22 | ||
PCT/US1999/005028 WO1999046281A2 (en) | 1998-03-10 | 1999-03-08 | Novel polypeptides and nucleic acids encoding the same |
WOPCT/US99/05028 | 1999-03-08 | ||
US13023299P | 1999-04-21 | 1999-04-21 | |
US130232P | 1999-04-21 | ||
US13144599P | 1999-04-28 | 1999-04-28 | |
US131445P | 1999-04-28 | ||
US13428799P | 1999-05-14 | 1999-05-14 | |
US134287P | 1999-05-14 | ||
US14475899P | 1999-07-20 | 1999-07-20 | |
US144758P | 1999-07-20 | ||
US14569899P | 1999-07-26 | 1999-07-26 | |
US145698P | 1999-07-26 | ||
WOPCT/US99/21547 | 1999-09-15 | ||
PCT/US1999/021090 WO2000015796A2 (en) | 1998-09-16 | 1999-09-15 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PCT/US1999/021547 WO2000015797A2 (en) | 1998-09-17 | 1999-09-15 | Compositions and methods for the treatment of immune related diseases |
WOPCT/US99/21090 | 1999-09-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69935085D1 true DE69935085D1 (en) | 2007-03-22 |
DE69935085T2 DE69935085T2 (en) | 2007-08-23 |
Family
ID=27557838
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69940964T Expired - Lifetime DE69940964D1 (en) | 1998-12-22 | 1999-12-02 | Methods and compositions for inhibiting neoplastic cell growth |
DE69935085T Expired - Lifetime DE69935085T2 (en) | 1998-12-22 | 1999-12-02 | Method and composition for inhibiting neoplastic cell growth |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69940964T Expired - Lifetime DE69940964D1 (en) | 1998-12-22 | 1999-12-02 | Methods and compositions for inhibiting neoplastic cell growth |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1141284A2 (en) |
JP (5) | JP3993746B2 (en) |
KR (1) | KR100499600B1 (en) |
AT (2) | ATE353339T1 (en) |
AU (1) | AU768230B2 (en) |
CA (1) | CA2353799A1 (en) |
DE (2) | DE69940964D1 (en) |
DK (1) | DK1484338T3 (en) |
ES (2) | ES2327785T3 (en) |
IL (3) | IL143031A0 (en) |
MX (1) | MXPA01006330A (en) |
PT (1) | PT1484338E (en) |
WO (1) | WO2000037638A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999066041A1 (en) | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
US6392019B1 (en) | 1997-11-22 | 2002-05-21 | John Ford | Antibodies specific for EGF motif proteins |
US6808890B2 (en) | 1999-07-28 | 2004-10-26 | Nuvelo, Inc. | Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
CA2309897A1 (en) | 1997-11-22 | 1999-06-03 | Hyseq, Inc. | A novel egf motif protein obtained from a cdna library of fetal liver-spleen |
NZ528700A (en) * | 1998-04-08 | 2005-02-25 | Genentech Inc | Novel PRO866 polypeptides and nucleic acids with homology to mindin and spondin proteins |
US6960433B1 (en) | 1998-10-19 | 2005-11-01 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating prostate cancer |
JP5550799B2 (en) | 1999-01-15 | 2014-07-16 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | TWEAK antagonists and TWEAK receptor antagonists and their use to treat immunological disorders |
KR100553300B1 (en) * | 1999-03-08 | 2006-02-20 | 제넨테크, 인크. | Promotion or Inhibition of Angiogenesis and Cardiovascularization |
ES2291198T3 (en) * | 1999-07-20 | 2008-03-01 | Genentech, Inc. | COMPOSITIONS AND PROCEDURES FOR THE TREATMENT OF IMMUNOLOGICAL TYPE DISEASES. |
IL149849A0 (en) * | 1999-12-09 | 2002-11-10 | Sankyo Co | A method and kit for testing an agent for treatment of hyperlipemia |
CZ20022438A3 (en) * | 2000-01-12 | 2002-10-16 | Yale University | Nucleic acid encoding Nogo receptor, isolated polypeptide, and pharmaceutical preparation for stimulating growth of axons |
US7119165B2 (en) | 2000-01-12 | 2006-10-10 | Yale University | Nogo receptor-mediated blockade of axonal growth |
JP2004500844A (en) | 2000-05-08 | 2004-01-15 | バイオジェン インコーポレイテッド | Method for promoting neovascularization using a TWEAK agonist and an angiogenic factor |
US7208151B2 (en) | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
JP4465148B2 (en) | 2000-10-06 | 2010-05-19 | イェール ユニバーシティー | Nogo receptor homolog |
US20020111302A1 (en) * | 2000-11-30 | 2002-08-15 | Y. Tom Tang | Novel nucleic acids and polypeptides |
DK1997512T3 (en) | 2002-04-09 | 2014-01-27 | Biogen Idec Inc | Methods for treating TWEAK-related conditions |
CA2391438A1 (en) * | 2002-05-01 | 2003-11-01 | Procyon Biopharma Inc. | Psp94 diagnostic reagents and assays |
CA2597945C (en) | 2005-02-17 | 2016-07-12 | Biogen Idec Ma Inc. | Treating neurological disorders |
CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
EP1904091A4 (en) | 2005-07-07 | 2009-12-23 | Univ Yale | Compositions and methods for suppressing axonal growth inhibition |
EP3299027A1 (en) | 2005-11-04 | 2018-03-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
WO2007117657A2 (en) * | 2006-04-07 | 2007-10-18 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US9044461B2 (en) | 2006-04-07 | 2015-06-02 | The Research Foundation Of State University Of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
US7776573B2 (en) | 2006-06-01 | 2010-08-17 | Genentech, Inc. | Crystal structure of CRIg and C3b:CRIg complex |
CA2939806A1 (en) | 2006-11-02 | 2008-05-08 | Genentech, Inc. | Humanized anti-factor d antibodies and uses thereof |
AR066660A1 (en) | 2007-05-23 | 2009-09-02 | Genentech Inc | PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT |
CR20170001A (en) | 2008-04-28 | 2017-08-10 | Genentech Inc | ANTI FACTOR D HUMANIZED ANTIBODIES |
RU2553517C2 (en) | 2008-05-06 | 2015-06-20 | Дженентек, Инк. | Affinity-matured crig versions |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
JP6463359B2 (en) | 2013-08-12 | 2019-01-30 | ジェネンテック, インコーポレイテッド | Compositions and methods for treating complement related conditions |
WO2015168468A1 (en) | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
CN108472382A (en) | 2015-10-30 | 2018-08-31 | 豪夫迈·罗氏有限公司 | Anti- factor D antibody variants conjugate and application thereof |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
CN114835774B (en) * | 2022-06-29 | 2022-09-27 | 中国农业大学 | Oligopeptide MSL separated from pepper seeds and application thereof in preventing or treating cancers |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ226799A (en) * | 1987-11-06 | 1991-08-27 | Oncogen | Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor |
US5814307A (en) * | 1989-04-10 | 1998-09-29 | Bristol-Myers Squibb Company | Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6 |
US5416192A (en) * | 1990-04-03 | 1995-05-16 | Bristol-Myers Squibb Company | Epithelins: novel cysteine-rich growth modulating proteins |
US5028099A (en) * | 1990-08-08 | 1991-07-02 | Bertucco Leonard J | Trash recycling container |
US6030831A (en) * | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
WO1999055869A1 (en) * | 1998-04-27 | 1999-11-04 | Zymogenetics, Inc. | Novel polypeptide growth factors and materials and methods for making them |
SV1999000069A (en) * | 1998-06-02 | 2000-04-11 | Lilly Co Eli | ANGIOPOYETIN RELATED TO SEQUENCE OF GEN 3 IN FACE SCAR REF. X-12261 |
JP7039446B2 (en) * | 2018-11-29 | 2022-03-22 | 株式会社東芝 | Electronic device |
-
1999
- 1999-12-02 DE DE69940964T patent/DE69940964D1/en not_active Expired - Lifetime
- 1999-12-02 ES ES07001711T patent/ES2327785T3/en not_active Expired - Lifetime
- 1999-12-02 IL IL14303199A patent/IL143031A0/en not_active IP Right Cessation
- 1999-12-02 DE DE69935085T patent/DE69935085T2/en not_active Expired - Lifetime
- 1999-12-02 KR KR10-2001-7007850A patent/KR100499600B1/en not_active IP Right Cessation
- 1999-12-02 MX MXPA01006330A patent/MXPA01006330A/en not_active Application Discontinuation
- 1999-12-02 WO PCT/US1999/028565 patent/WO2000037638A2/en active Search and Examination
- 1999-12-02 AT AT04007617T patent/ATE353339T1/en active
- 1999-12-02 AT AT07001711T patent/ATE432987T1/en not_active IP Right Cessation
- 1999-12-02 ES ES04007617T patent/ES2281704T3/en not_active Expired - Lifetime
- 1999-12-02 AU AU17499/00A patent/AU768230B2/en not_active Expired
- 1999-12-02 CA CA002353799A patent/CA2353799A1/en not_active Abandoned
- 1999-12-02 DK DK04007617T patent/DK1484338T3/en active
- 1999-12-02 EP EP99960644A patent/EP1141284A2/en not_active Withdrawn
- 1999-12-02 JP JP2000589692A patent/JP3993746B2/en not_active Expired - Fee Related
- 1999-12-02 PT PT04007617T patent/PT1484338E/en unknown
-
2005
- 2005-03-10 JP JP2005066570A patent/JP2005237383A/en not_active Withdrawn
- 2005-03-10 JP JP2005066569A patent/JP4037876B2/en not_active Expired - Lifetime
-
2007
- 2007-05-24 JP JP2007138468A patent/JP2007222180A/en active Pending
- 2007-05-24 JP JP2007138469A patent/JP2007291116A/en active Pending
- 2007-09-20 IL IL186153A patent/IL186153A0/en unknown
- 2007-09-20 IL IL186154A patent/IL186154A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL186153A0 (en) | 2008-01-20 |
JP2007291116A (en) | 2007-11-08 |
IL143031A0 (en) | 2002-04-21 |
DE69940964D1 (en) | 2009-07-16 |
DE69935085T2 (en) | 2007-08-23 |
ATE432987T1 (en) | 2009-06-15 |
AU768230B2 (en) | 2003-12-04 |
KR20010084882A (en) | 2001-09-06 |
JP2005237383A (en) | 2005-09-08 |
ES2281704T3 (en) | 2007-10-01 |
DK1484338T3 (en) | 2007-06-11 |
WO2000037638A2 (en) | 2000-06-29 |
ES2327785T3 (en) | 2009-11-03 |
JP2007222180A (en) | 2007-09-06 |
WO2000037638A3 (en) | 2000-11-09 |
IL186154A0 (en) | 2008-01-20 |
EP1141284A2 (en) | 2001-10-10 |
KR100499600B1 (en) | 2005-07-07 |
ATE353339T1 (en) | 2007-02-15 |
JP2005245451A (en) | 2005-09-15 |
AU1749900A (en) | 2000-07-12 |
JP4037876B2 (en) | 2008-01-23 |
CA2353799A1 (en) | 2000-06-29 |
JP3993746B2 (en) | 2007-10-17 |
PT1484338E (en) | 2007-05-31 |
MXPA01006330A (en) | 2002-07-02 |
JP2003529317A (en) | 2003-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69935085D1 (en) | Method and composition for inhibiting neoplastic cell growth | |
ATE357518T1 (en) | METHODS AND COMPOSITIONS FOR INHIBITING NEOPLASTIC CELL GROWTH | |
ATE408419T1 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF A TUMOR | |
ATE380195T1 (en) | COMPOSITIONS AND METHODS FOR TREATING TUMORS | |
IL193149A (en) | Anti il-17c antibody and therapeutic compositions comprising same | |
HK1114636A1 (en) | 1l-17 homologous polypeptides and therapeutic uses thereof | |
WO2002026822A3 (en) | Pumpcn compositions and uses thereof | |
MXPA01002592A (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same. | |
DE60043125D1 (en) | Compositions and methods for tumor treatment | |
KR100468977B1 (en) | Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same | |
DE69940681D1 (en) | Composition and method for the diagnosis of tumors | |
WO2000032778A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
WO2001049715A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
EP2075335A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
EP1820860A3 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
KR100515858B1 (en) | PRO617 Polypeptides | |
WO2000007545A8 (en) | Apoptosis proteins | |
KR100515857B1 (en) | PRO792 Polypeptides | |
KR100515855B1 (en) | PRO351 Polypeptides | |
KR100515856B1 (en) | PRO618 Polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |